This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) stock fell 6% after the medical device maker cut its Q4 sales and full-year EPS guidance due to ongoing disruptions from an August cyberattack. The company estimated the eight-day cyberattack cost it 300 basis points in sales growth and $0.07 in adjusted EPS. Management expects a slow recovery with 2027 projected as the trough year, though the stock now trades at a relatively low 13x forward earnings multiple.

Abbott Receives FDA Approval For First And Only Device In The U.S. To Treat Leaks After Heart Valve Replacement Without Additional Surgery

Abbott's Role in the Growing Global Leadless Pacemaker Market

Abbott continues to address clinical needs in the leadless pacemaker market with its AVEIR DR system as the industry projects significant growth through 2036.

BOH Expands Buyback Plan: Can It Sustain Strong Capital Returns?

Bank of Hawaii (BOH) expanded its share repurchase authorization by $200 million to $268.7 million, reflecting management confidence in its financial position. The company reported 20.5% year-over-year net income growth to $64.3 million in Q3 2026, with net interest income rising 14.2% and the net interest margin expanding for the tenth consecutive quarter. BOH maintains strong capital ratios and liquidity, supporting continued shareholder distributions including a 4.3% dividend yield.

Keefe, Bruyette & Woods Downgrades Bank of Hawaii to Market Perform

Analyst firm Keefe, Bruyette & Woods has downgraded Bank of Hawaii Corporation from Outperform to Market Perform, setting a price target of $78.

Bank of Hawaii Reports Q3 2026 Financial Results

Bank of Hawaii Corporation announced its third-quarter 2026 financial results, reporting revenue and earnings that fell short of analyst consensus estimates.